Table 2—

Number of high-risk diabetic patients with antiplatelet drug prescriptions at baseline and at the end of the follow-up

Control
Intervention
OR (95% CI)
High-risk diabetic subjects (n)Antiplatelet users
High-risk diabetic subjects (n)Antiplatelet users
Type of risk*Baseline (%)Follow-up (%)Effect size (%)Baseline (%)Follow-up (%)Effect size (%)
Group 12,578263 (10.2)440 (17.1)177 (6.9)2,651358 (13.5)736 (27.8)378 (14.3)2.38 (1.97–2.87)
Group 21,440180 (12.5)276 (19.2)9.6 (6.7)1,577224 (14.2)508 (32.2)284 (18.0)3.22 (2.52–4.12)
Group 33,2951,229 (37.3)1,526 (46.3)297 (9.0)3,8021,304 (34.3)1,768 (46.5)464 (12.2)1.36 (1.16–1.59)
Total7,3131,672 (22.9)2,242 (30.7)570 (7.8)8,0301,886 (23.5)3,012 (37.5)1,126 (14.0)1.99 (1.79–2.22)
  • Data are n (%).

  • *

    * Group 1: one risk factor without CVDs; group 2: two or more risk factors without CVDs; group 3: presence of at least one CVD;

  • P < 00.1 for follow-up vs. baseline.